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Background and purpose — In some patients, for unknown rea-
sons pain persists after joint replacement, especially in the knee. 
We determined the prevalence of persistent pain following pri-
mary hip or knee replacement and its association with disorders 
of glucose metabolism, metabolic syndrome (MetS), and obesity.
Patients and methods — The incidence of pain in the operated 
joint was surveyed 1–2 years after primary hip replacement (74 
patients (4 bilateral)) or primary knee replacement (119 patients 
(19 bilateral)) in 193 osteoarthritis patients who had participated 
in a prospective study on perioperative hyperglycemia. Of the 
155 patients who completed the survey, 21 had undergone fur-
ther joint replacement surgery during the follow-up and were 
excluded, leaving 134 patients for analysis. Persistent pain was 
defined as daily pain in the operated joint that had lasted over 3 
months. Factors associated with persistent pain were evaluated 
using binary logistic regression with adjustment for age, sex, and 
operated joint.
Results — 49 of the134 patients (37%) had a painful joint and 
18 of them (14%) had persistent pain. A greater proportion of 
knee patients than hip patients had a painful joint (46% vs. 24%; 
p = 0.01) and persistent pain (20% vs. 4%; p = 0.007). Previously 
diagnosed diabetes was strongly associated with persistent pain 
(5/19 vs. 13/115 in those without; adjusted OR = 8, 95% CI: 2–38) 
whereas MetS and obesity were not. However, severely obese 
patients (BMI ≥ 35) had a painful joint (but not persistent pain) 
more often than patients with BMI < 30 (14/21 vs. 18/71; adjusted 
OR = 5, 95% CI: 2–15).
Interpretation — Previously diagnosed diabetes is a risk factor 
for persistent pain in the operated joint 1–2 years after primary 
hip or knee replacement.

Many patients continue to experience pain after joint replace-
ment. Persistent pain is defined as pain that develops after 
surgery and that has been present for over 3 months (Interna-
tional Association for the Study of Pain 1986) and its preva-
lence is underestimated (Visser 2006). According to Beswick 
et al. (2012), at least 5–21% of hip replacement recipients and 
8–27% of knee replacement recipients suffer from persistent 
pain postoperatively.
Persistent pain is generally thought to be of neuropathic 
origin and caused by perioperative nerve damage (Kehlet et 
al. 2006). However, neuropathic pain appears to be rare in 
joint replacement patients (Wylde et al. 2011). Instead, these 
patients often describe their pain in a way that indicates the 
presence of an inflammatory factor (Wylde et al. 2011). The 
degree of the inflammatory state is associated with the severity 
of preoperative pain in patients with osteoarthritis (Stürmer 
et al. 2004). In addition, the intensity and duration of preop-
erative pain correlates with persistent postoperative pain in 
knee replacement surgery (Lundblad et al. 2008, Puolakka 
et al. 2010). Other established risk factors for persistent pain 
include genetic factors, history of preoperative pain, depres-
sion, existence of other chronic pain sites, and psychosocial 
factors (Kehlet et al. 2006, Nikolajsen et al. 2006, Rolfson et 
al. 2009).
Low-grade systemic inflammation is associated with the 
pathogenesis of diabetes, metabolic syndrome (MetS; a clus-
tering of cardiovascular risk factors including abdominal 
obesity, hypertension, dyslipidemia, and impaired glucose 
metabolism (Alberti et al. 2009)), and obesity. All these con-
ditions are common in joint replacement recipients (Meding 
et al. 2007, Gonzales Della Valle et al. 2012, Workgroup of 
the American Association of Hip and Knee Surgeons Evi-
dence Based Committee 2013). Diabetes is associated with 
poor postoperative outcomes, including reduced joint func-
tion (Robertson et al. 2012) and slower recovery in terms of 
pain and function (Jones et al. 2012). Obesity is associated 
with slower recovery, especially in knee patients (Workgroup 
of the American Association of Hip and Knee Surgeons Evi-
dence Based Committee 2013). It has been hypothesized 
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that the systemic proinfammatory state in MetS negatively 
affects patients’ function and recovery after joint replacement 
(Gandhi et al. 2010). To our knowledge, the effect of disorders 
of glucose metabolism, MetS, and obesity on persistent pain 
after joint replacement has not been studied previously.
We therefore determined whether glucose metabolism dis-
orders, MetS, and obesity are associated with persistent pain 
in the operated joint 1–2 years after primary joint replacement.
Patients and methods
Between December 2009 and May 2011, 200 patients sched-
uled for primary hip or knee replacement for osteoarthritis in 
a single orthopedic hospital were recruited in a prospective 
study concerning perioperative hyperglycemia (“Perioperative 
hyperglycemia in primary total hip and knee replacement”; 
clinicaltrials.gov identifier NCT01021826). Patients of all 
ages with or without previously diagnosed diabetes were eli-
gible. The exclusion criteria were an arthritis diagnosis other 
than osteoarthritis and regular oral corticosteroid treatment. 
The patients were closely comparable to other patients under-
going primary hip or knee replacement for osteoarthritis in 
the same hospital during the study period (n = 2,565) in terms 
of sex (the proportion of females in the study population was 
65% as compared to 63% in the other patients; p = 0.6) and in 
terms of joint operated (the proportion of knee replacements 
in the study population was 61% as compared to 57% in the 
other patients; p = 0.3), but the mean age was lower in the 
study population (66 (SD 9) years vs. 68 (SD 11) years; p = 
0.002).
Of the 200 patients, 191 were operated on and were enrolled 
in this prospective observational follow-up study. Pain in the 
operated joint was surveyed 1–2 years after the operation, 
using a postal questionnaire. The response rate was 81% 
(155/191). After exclusion of patients who had undergone 
later operations, the study population consisted of 134 patients 
(80 knee patients and 54 hip patients) (Figure).
The study protocol concerning preoperative diagnostics, 
perioperative treatment, and postoperative care has been 
described previously in detail (Jämsen et al. 2014). In short, 
a research nurse evaluated the patients carefully 6–8 weeks 
before surgery and recorded their medical history. 
In addition to preoperative laboratory routines, measure-
ments were performed to diagnose MetS and diabetes, as these 
conditions are often undiagnosed in many patients (Meding et 
al. 2007). Thus, diagnoses based on patient reports or patient 
records are not reliable. Fasting plasma glucose, blood glyco-
sylated hemoglobin A1 (HbA1c), and plasma lipids (LDL and 
HDL cholesterol, triglycerides) were measured in all patients. 
Patients without previously diagnosed diabetes had a 2-hour 
oral glucose tolerance test with an oral glucose dose of 75 g 
(WHO 2006).
Patient characteristics (Table 1)
Almost half of the patients were obese (BMI ≥ 30). The preva-
lence of diabetes was 25% (34/134), and 24% (32/134) had 
increased fasting glucose (IFG) or impaired glucose tolerance 
(IGT). 19 patients were already diagnosed as having diabetes 
before recruitment, 4 of whom were being treated with insu-
lin, and 15 patients were diagnosed in this study. Almost two-
thirds of the patients had MetS. The median (range) duration 
of follow-up was 18 (11–28) months. No statistically signifi-
cant differences in age, sex, operated joint, BMI, prevalence 
of glucose metabolism disorders, or prevalence of MetS were 
found between those who responded to the questionnaire and 
those who did not.
Severely obese participants were significantly younger 
(median 63 years) than obese participants (median 66 years) 
and non-obese participants (median 68 years) (p = 0.02). 
Men more often had IFG or IGT (31% vs. 20%) and diabe-
tes (33% vs. 21%) than women (p = 0.04). Also, MetS was 
more common in men (76% vs. 57%, p = 0.04). Median BMI 
was higher in patients with diabetes (33) and IFG or IGT (30) 
than in patients with normal glucose metabolism (27; p = 
0.002). Patients with MetS were significantly more obese than 
patients without MetS (median BMI 32 vs. 27; p < 0.001). The 
severity of preoperative pain at rest was milder in patients with 
disorders of glucose metabolism (Table 2). No significant dif-
ferences were found between the subgroups of patients with 
glucose metabolism disorders, MetS, or obesity regarding 
joint replaced, proportion of bilateral operations, proportion 
Figure. Patient recruitment.          
Excluded (n = 7):
– patient cancelled the operation, 2
– withdrew, 2
– operation cancelled for health-related reasons, 3
Excluded (n = 57):
– did not answer the postal questionnaire, 36
– had joint replacement in another joint during 
   follow-up, 19
– was revised, 2
Excluded (n = 2):
– inadequate postoperative glucose monitoring
Patients operated
n = 193
Included in a study concerning
perioperative hyperglycemia
n = 191
Included
n = 134
(54 hip and 80 knee patients)
Patients recruited
n = 200
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of unicompartmental knee replacements, proportion of former 
joint replacements, average follow-up time, and severity of 
osteoarthritis, as assessed with the Kellgren-Lawrence grad-
ing scale (data not shown).
The operations were mainly performed by experienced 
senior orthopedic surgeons. All operations were performed 
under spinal anesthesia. Acetaminophen and/or a non-steroi-
dal anti-inflammatory drugs were used as routine analgesics 
and they were supplemented with oxycodone when necessary. 
Epidural analgesia using a continuous levobupivacaine infu-
sion (1.25 mg/mL) was inserted if needed after routine and 
supplementary medication. Most of the operations were uni-
lateral (90%) and a total joint replacement was implanted in 
all patients except for 8  unicompartmental knee replacements 
(6%). Most of the knee replacements were cemented (74%) 
whereas hip replacements were mostly cementless (67%). 
Antibiotic-impregnated cement was used in all cemented joint 
replacements. A pneumatic tourniquet was used in all knee 
replacements. Median length of hospital stay was 4 (1–6) days.
Outcomes
The primary outcome was occurrence of persistent pain in the 
operated joint. The pain questions were based on the classifi-
cation of chronic pain (International Association for the Study 
of Pain 1986) and they were as follows: “Do you have pain in 
the operated knee or hip?”, “Is there pain in the operated knee 
or hip every day?” and “Has the pain in the operated knee or 
hip been there continuously for over 3 months?”. The patient 
was deemed to have persistent pain if he or she answered 
“yes” to all 3 questions. Prevalence of having a painful joint 
was a secondary outcome and it was assessed by the answer to 
the first pain question.
The Finnish version of the PainDetect questionnaire (Freyn-
hagen et al. 2006) was included in the postal questionnaire 
to determine whether the pain reported was of neuropathic 
origin. The PainDetect questionnaire was originally developed 
for patients with back pain, but it has also been used to exam-
ine postoperative pain in joint replacement patients (Wylde et 
al. 2011).
Statistics
The analyses were done for subgroups of patients according to 
whether they had disorders of glucose metabolism, had MetS, 
or were obese. In order to maximize statistical power, knee 
and hip replacements were analyzed together, but the analyses 
were also re-run separately.
The disorders of glucose metabolism were categorized 
according to the WHO recommendation (WHO 2006) as fol-
lows: normal glucose metabolism, IFG and/or IGT, and diabe-
tes. The categorization was based either on self-reported diag-
nosis of diabetes with confirmed medication or on the result of 
an oral glucose tolerance test in this study. The patients with 
previously and newly diagnosed diabetes were analyzed both 
separately and by combining the groups. MetS was defined 
Table 1. Baseline characteristics (n = 134)
Age, median (range), years 67 (42–89)
Gender: female, n (%) 89 (66)
BMI, median (range) 29 (21–49)
Subgroups of obesity, n (%), median BMI 
 < 30 71 (53), 26
 30–35 42 (31), 33
 ≥ 35 21 (16), 38
Glucose metabolism, n (%) 
 Normal,  68 (51)
 IFG/IGT 32 (24)
 Diabetes  
  Previously diagnosed 19 (14)
  Newly diagnosed 15 (11)
Metabolic syndrome, n (%) 85 (63)
Operated joint, n (%) 
 Hip 54 (40)
 Knee 80 (60)
Bilateral operation, n 
(% of hip/knee replacement patients) 
 Hip   4 (7)
 Knee 10 (13)
Kellgren-Lawrence rating, n (%) 
 1    0 (0)
 2  24 (18)
 3  56 (42)
 4  51 (38)
Earlier joint replacement, n (%) 26 (19)
ASA rating, n (%) 
 1  10 (8)
 2  65 (49)
 3  58 (43)
 4    1 (1)
Smoker, n (%) 12 (9)
Preoperative pain, VAS, median (range) a 
 At rest 39 (1–97)
 In motion  81 (4–99)
Duration of follow-up, median (range), months 18 (11–28)
IFG: increased fasting glucose;  
IGT: impaired glucose tolerance; 
VAS: visual analog scale (0–100)
a 82% (110/134) had filled in the VAS scale. 
Table 2. Preoperative pain by vas scale (0–100) in 110 patients who 
filled in the vas scale. values are median (range).
 Preoperative Preoperative
 pain at rest pain in motion
 n VAS p-value VAS p-value
All materials 110 39 (1–97)  81 (4–99) 
Glucose metabolism   0.01  0.09
 Normal 50 46 (1–97)  81 (18–99) 
 IFG/IGT 30 29 (1–80)  85 (5–98) 
 Diabetes a 30 24 (1–96)  79 (4–98) 
BMI   0.3  0.05
 < 30 60 45 (1–97)  82 (4–98) 
 30–34.9 33 29 (1–84)  75 (46–99) 
 ≥ 35 17 25 (1–85)  83 (47–97) 
Metabolic syndrome   0.6  1.0
 No 41 37 (1–97)  81 (5–98) 
 Yes 69 42 (1–97)  79 (4–99) 
For abbreviations, see Table 1.
a Includes both previously and newly diagnosed cases of diabetes.
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according to the consensus criteria (Alberti et al. 2009), and 
its impact was also studied separately in patients with and 
without diabetes. BMI was analyzed both as a continuous 
variable and as a categorized variable. 3 groups were formed 
to maximize the statistical power as follows: normal or over-
weight (< 30), obese (30–34.9), and severely obese (≥ 35). In 
patients with diabetes, the effect of glucose control was evalu-
ated by comparing patients with HbA1c < 6.5% and those 
with HbA1c ≥ 6.5% (Kowall and Rathmann 2013).
Associations between disorders of glucose metabolism, 
MetS, and obesity with a painful joint or persistent pain were 
first analyzed using cross-tabulation and the chi-squared test. 
Then, a binary logistic regression model with adjustment for 
age, sex, and operated joint was used to calculate respective 
odds ratios (ORs) and 95% confidence intervals (CIs).
Ethics and registration
The study was performed in accordance with the Declaration 
of Helsinki. The research plan was approved by the Ethics 
Board of Pirkanmaa Hospital District, Tampere, Finland 
(R12071; April 22, 2012). All the patients gave informed con-
sent before participation. The study was registered at Clinical-
Trials.gov (identifier NCT01743313).
Results
49 patients (37%) had a painful joint. 18 of them (14% of the 
whole series) fulfilled the criteria of having persistent pain. 
The occurrence of persistent pain in 2 other patients was 
unclear because of missing answers to some of the 3 questions 
required for diagnosis.
Knee patients were more likely than hip patients to have 
a painful joint (46% vs. 24%; p = 0.01) and to suffer from 
persistent pain (20% vs. 4%; p = 0.007). Of 8 unicompartmen-
tal knee replacements in our material, 1 patient had persistent 
pain. According to the PainDetect questionnaire, the nature of 
pain was neuropathic in 2 of the 49 patients with a painful 
joint (4%). Both patients also fulfilled the criteria of having 
persistent pain. 
Previously diagnosed diabetes was a significant risk factor 
for having persistent pain, but not for having a painful joint 
(Table 3). Other glucose metabolism disorders and MetS were 
not associated with a painful joint or persistent pain. A higher 
proportion of severely obese patients had a painful joint than 
patients with BMI < 30. The results concerning the effects of 
diabetes and severe obesity did not change when ASA score 
and BMI were added to the adjusted models: OR for persis-
tent pain in patients with previously diagnosed diabetes was 
20 (CI: 3–132) and OR for a painful joint in severely obese 
patients was 4 (CI: 1.3–14).
The influence of obesity on the prevalence of a painful joint 
was similar in knee and hip patients. 14 of 39 non-obese knee 
patients, 11 of 26 obese knee patients, and 11 of 14 severely 
obese knee patients had a painful joint (p = 0.02), and the cor-
responding proportions of hip patients were 4/32, 6/15, and 
3/7, respectively (p = 0.05). Also, a higher proportion of hip 
patients with MetS had a painful joint (12/36) than hip patients 
without MetS (1/18) (p = 0.04). Previously diagnosed diabetes 
was associated with persistent pain in hip patients (2/10 vs. 
Table 3. Potential risk factors for a painful joint and persistent pain 
 Painful joint (n = 49; 37%) Persistent pain (n = 18; 14%)
     Adjusted c   Adjusted c
  N  n (%) OR (95% CI) OR (95% CI) n (%) OR (95% CI) OR (95% CI)
Previously diagnosed diabetes        
 No a 115 41 (36) 1 1 13 (11) 1 1
 Yes 19   8 (44) 1.4 (0.5–3.9) 2.2 (0.7–6.3)   5 (28) 3.0 (0.9–9.7) 8.5 (1.9–38)
Glucose metabolism abnormalities        
 No 68 24 (35) 1 1   8 (12) 1 1
 IFG/IGT 32 12 (38) 1.1 (0.5–2.6) 1.2 (0.5–3.1)   4 (13) 1.1 (0.3–4.0) 1.1 (0.3–4.5)
 Diabetes** 34 13 (39) 1.2 (0.5–2.8) 1.7 (0.7–4.5)   6 (18) 1.7 (0.5–5.3) 3.2 (0.9–12)
Metabolic syndrome        
 No 49 15 (31) 1 1   8 (16) 1 1
 Yes, but without diabetes 54 21 (39) 1.4 (0.6–3.3) 1.5 (0.6–3.5)   4 (8) 0.4 (0.1–1.5) 0.3 (0.07–1.2)
 Yes and with diabetes b 31 13 (43) 1.7 (0.7–4.5) 2.6 (0.9–7.3)   6 (20) 1.3 (0.4–4.1) 2.3 (0.6–8.9)
BMI        
 < 30 71 18 (25) 1 1   8 (11) 1 1
 30–34.9 42 17 (42) 2.1 (0.9–4.7) 1.9 (0.8–4.3)   6 (15) 1.3 (0.4–4.1) 1.0 (0.3–3.4)
 ≥ 35 21 14 (67) 5.9 (2.1–17) 5.0 (1.7–15)   4 (19) 1.8 (0.5–6.8) 1.1 (0.3–4.7)
BMI (per increase of 1 kg/m²)   1.1 (1.0–1.2) 1.1 (1.0–1.2)  1.0 (0.9–1.1) 1.0 (0.9–1.1)
For abbreviations, see Table 1.
a A patient without diabetes or with IFG, IGT, or diabetes mellitus diagnosed in this study.
b Includes both previously and newly diagnosed cases of diabetes.
c Adjusted for age, gender, and operated joint (hip or knee). 
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0/43; p = 0.03) but not in knee patients (3/8 vs. 13/71; p = 0.3). 
However, in a post-hoc analysis the statistical power in these 
analyses (with the probability of type 1-error set to 5%) turned 
out to be low for both hip and knee replacements: 47% and 
83% for the effect of obesity on a painful joint (severely obese 
vs. non-obese), and 71% and 30% for the effect of diabetes on 
persistent pain, respectively.
In patients with diabetes, preoperative HbA1c was not asso-
ciated  with a painful joint (7/14 and 13/19 in patients with 
HbA1c < 6.5% and ≥ 6.5%, respectively; p = 0.3) or persistent 
pain (3/14 and 3/19; p = 1.0).
To study the influence of recovery time on the prevalence 
of pain, the patients were categorized into 3 groups based on 
the length of the follow-up time: < 15 months (55 patients), 
15–21 months (51 patients), and > 21 months (28 patients). 
No statistically significant differences were found in these 
groups regarding diabetes, MetS, and different groups of BMI 
(data not shown). Similar proportions of patients in the differ-
ent follow-up time groups had a painful joint (20/55, 21/51, 
and 8/27, respectively; p = 0.6). However, 10 of the 54 patients 
with the shortest follow-up time and 8 of the 51 patients with 
a follow-up time of 15–21 months reported having persistent 
pain, but none of the 27 patients with follow-up time of over 
21 months reported having persistent pain (p = 0.04).
92% of the patients answered that they had less pain at rest 
and 89% had less pain when in motion relative to the situation 
preoperatively. Even so, 8% of the patients had no improve-
ment in pain (or had more pain) at rest, and 11% had no 
improvement in pain (or had more pain) in motion. The poor 
pain relief was common in patients with previously diagnosed 
diabetes—of whom 3/16 had no improvement (or had more 
pain) at rest (6/92 among the others; p = 0.1) and 5/17 had no 
improvement (or had more pain) in motion (7/93 among the 
others; p = 0.02). MetS and obesity were not associated with 
poor pain relief (data not shown).
Discussion
This prospective study confirms earlier results (Nikolajsen et 
al. 2006, Puolakka et al. 2010, Beswick et al. 2012) indicating 
that pain in the operated joint is a common problem following 
primary hip and knee replacement, even after an uncompli-
cated postoperative course: one-third of patients had a pain-
ful joint and 14% had persistent pain. Our findings suggest 
that previously diagnosed diabetes is a risk factor for persis-
tent pain whereas severe obesity is a risk factor for a painful 
joint 1–2 years after the operation. Other disorders of glucose 
metabolism and MetS were not associated with the prevalence 
of a painful joint or persistent pain. The prevalence of neuro-
pathic pain was very low in our material. This supports the 
former findings that although neuropathic pain is common in 
other types of surgeries (Kehlet et al. 2006), the reason for per-
sistent pain in joint replacement patients is something else—
perhaps a low-grade inflammatory process with sensitization 
in the mechanisms of pain perception (Stürmer et al. 2004, 
Wylde et al. 2011).
Our main finding is that previously diagnosed diabetes is 
predictive of persistent pain in joint replacement patients with 
osteoarthritis. The difference appeared to be more pronounced 
in the hip replacement group, in which postoperative pain was 
otherwise less common than in the knee replacement group; 
but we acknowledge that this conclusion is based on relatively 
few patients. To our knowledge, there have been no earlier 
studies on the association between diabetes and persistent pain 
after joint replacement. Earlier, Gandhi et al. (2010) reported 
that diabetes was not an independent predictor of poor func-
tional outcome or improvement in pain, measured at 1 year 
using WOMAC, although a trend could also be seen in that 
study. Jones et al. (2012) observed that recovery in terms of 
pain and function after total knee replacement was slower after 
3 months to 3 years in patients with diabetes than in patients 
without diabetes. In both of these studies, the diagnoses of dia-
betes were based only on patients’ self-reported information 
or medical charts, whereas in our study patients without previ-
ously diagnosed diabetes had an oral glucose tolerance test in 
order to identify underlying disorders of glucose metabolism. 
Studies both in the general population and in joint replace-
ment recipients have indicated that diabetes is underdiagnosed 
and that the real number of patients with diabetes is twice as 
much as originally believed (Meding et al. 2007). Because of 
the careful diagnosis of diabetes in our study, we believe that 
the results reflect the actual situation more precisely and our 
findings that newly diagnosed diabetes, IFG, and IGT are not 
associated with a painful joint or persistent pain are reliable. 
Furthermore, unlike the earlier studies, we used the interna-
tional classification of persistent pain as primary outcome.
Patients with diabetes are in a chronic systemic proinflam-
matory state (van Greevenbroek et al. 2013). It has been 
shown that in patients with osteoarthritis, the degree of the 
patient’s inflammatory state is associated with the severity of 
preoperative pain (Stürmer et al. 2004). There is also a correla-
tion between the severity of preoperative pain and the sever-
ity of postoperative pain (Kehlet et al. 2006), which is a risk 
factor for persistent pain (Puolakka et al. 2010). Contradicting 
our expectations based on these earlier results, patients with 
diabetes had least pain, as measured using visual analog scale 
(VAS), preoperatively but still increased risk for persistent 
pain after surgery.
Other factors that could explain persistent pain in patients 
with diabetes are glucose control and diabetes-related compli-
cations, such as neuropathy. In the present study, we catego-
rized diabetes into only 2 subgroups depending on whether it 
was diagnosed during the study or previously. This categoriza-
tion did not allow us to examine the influence of poor long-
term blood glucose equilibrium, or how long the previously 
diagnosed diabetic patient had suffered from diabetes. It is 
generally thought that blood HbA1c represents the long-term 
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equilibrium of blood glucose levels in patients with diabetes. 
However, a single HbA1c measurement represents a patient’s 
blood glucose equilibrium from the previous 3 months only. 
Recent studies have shown that complications related to high 
blood glucose, such as neuropathy, need more time to develop 
and are rather related to long-term mean HbA1c or HbA1c 
variability (Kilpatrick 2012). No statistically significant asso-
ciations between HbA1c and the pain outcomes were found in 
the present study either.
Interestingly, none of the patients had persistent pain after a 
follow-up time of 21 months. It may be that in joint replace-
ment patients, the improvement in pain continues even after 1 
year or more. Alternatively, it may be that patients with diabe-
tes in particular require more time to reach full recovery. As 
there were only 2 patients with previously diagnosed diabetes 
in the group with the longest follow-up (which was also the 
smallest group), our study does not allow us to draw any con-
clusions on this issue. The definition of persistent pain (Inter-
national Association for the Study of Pain 1986) does not 
preclude the possibility that patients may recover from per-
sistent postoperative pain. The prognosis of persistent pain is 
unknown, but it appears that the prevalence of pain decreases 
as time goes by. Brander et al. (2003) found that the preva-
lence of  substantial pain decreased from 23% after 3 months 
to 19% after 6 months, and 13% after 12 months following 
total knee replacement.
A higher proportion of severely obese patients had a pain-
ful joint than in the group of normal or overweight patients, 
whereas obesity was not associated with persistent pain. There 
is conflicting literature concerning the influence of obesity on 
the outcomes of joint replacement. According to some studies, 
obesity does not affect the outcomes while in others a negative 
effect could be seen (Workgroup of the American Association 
of Hip and Knee Surgeons Evidence Based Committee 2013). 
Singh and Lewallen (2010) reported that severe and morbid 
obesity are significant predictors of moderate-to-severe pain 
after total hip replacement at 2-year follow-up and 5-year 
follow-up. Investigations of satisfaction with joint replace-
ment have not shown any statistically significant differences 
between obese and non-obese patients, yet morbid obesity 
(BMI > 40) appears to be a threshold for worse outcomes 
(Workgroup of the American Association of Hip and Knee 
Surgeons Evidence Based Committee 2013). However, in our 
study BMI was statistically significantly associated with a 
painful joint even as a continuous variable. 
Regarding the effect of MetS, Gandhi et al. (2010) reported 
that patient function and pain following joint replacement 
were negatively affected by the increasing number of meta-
bolic abnormalities related to MetS. We did not find any asso-
ciations between MetS and the prevalence of a painful joint, or 
persistent pain. The small sample size in our study may have 
biased our results, since closer examination of the number of 
individual components of MetS was not reasonable. On the 
other hand, in the study by Gandhi et al., no clinical exami-
nation was made and the diagnosis of MetS was based only 
on patients’ self-reported information about metabolic abnor-
malities. In earlier studies,  poorly controlled MetS has been 
associated with perioperative surgical and medical complica-
tions after total joint replacement (Gonzales Della Valle et al. 
2012, Zmistowski et al. 2013). We excluded patients with later 
joint replacements, but we did not analyze the other compli-
cations; nor did Gandhi et al. (2010), so we cannot preclude 
the possibility that complications could explain the conflicting 
results regarding pain.
The main strengths of the present study were its prospec-
tive nature and careful preoperative evaluation, with accu-
rate detection of disturbances in glucose metabolism and 
other metabolic abnormalities. Persistent pain, our primary 
outcome measure, was defined in accordance with an inter-
national, generally accepted definition (International Asso-
ciation for the Study of Pain 1986). A more recent definition 
has also been published (Macrae and Davies 1999), in which 
the borderline for persistent pain is defined to be at least 2 
months—instead of the 3 months used in the older definition. 
We decided to use the more strict definition with a 3-month 
limit, because it is reasonable to assume that 2 months is not 
enough in joint replacement patients. It has also been recom-
mended by the IMMPACT consensus meeting (Dworkin et al. 
2010) that a longer borderline should be used, at least in ran-
domized trials. In previous studies, different definitions have 
been used for persistent pain (Macrae 2008). Our institution 
is a high-volume center for joint replacement surgery, and the 
interventions and perioperative care were highly standardized 
and remained essentially unchanged during the study period. 
Most of the operations were performed by experienced joint 
replacement surgeons with high numbers of surgeries annu-
ally. Thus, variation in the treatment hardly biases our results. 
The response rate was rather good (82%). Patients who had 
revision surgery or another primary joint replacement in the 
study period were excluded, so the shortened recovery time of 
these patients would not bias our findings. 
The study also had some weaknesses. Since its design was 
based on a research project on perioperative hyperglycemia, 
the number of patients was small from the point of view of 
analyzing the prevalence of and predictors of persistent pain. 
Exclusion of patients who had had later surgeries further 
reduced the number of patients available. Because of the small 
study population, we could not run a multifactorial analysis 
to examine whether diabetes was an independent risk factor 
for persistent pain. Furthermore, post-hoc power analysis 
indicated that our sample size was insufficient for appropri-
ate joint-specific analysis. Such an analysis would have been 
important, because the etiology of persistent pain in joint 
replacement patients is not well known and it may be differ-
ent after hip and knee replacement. The conclusions are based 
on a small absolute number of cases. In addition, we did not 
have information about the complications of diabetes, such 
as peripheral neuropathy, which might have been a relevant 
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factor in explaining the results. Patients with diabetes may 
have more comorbidities such as depression and anxiety, and 
it cannot be ruled out that these comorbidities would explain 
the high prevalence of persistent pain in these patients. Acute 
postoperative pain is another factor that could have biased our 
results, since it is a risk factor for persistent pain, and we had 
no data on this. Because the study was started after the first 
surgeries in our series, there was some variation in follow-up 
times. However, even the patients with the shortest follow-up 
times should have had enough time to recover from surgery 
and early postoperative pain. Our materials do not represent 
a consecutive series of patients scheduled for surgery, but the 
patients were instead recruited in several (irregular) phases 
between 2009 and 2011.
Since pain in the operated joint was assessed with a postal 
questionnaire, we cannot be entirely sure that the patient’s 
answer concerned only the joint operated in this study. Selec-
tion bias is possible with patients who are planned for staged 
bilateral surgeries—and who were excluded from the present 
analysis—since they may have been older or have had more 
comorbidities than the patients included. Comorbidities of 
the patients may have also biased our results, since we were 
unable to take either individual comorbidities or the number 
of them into account. The ASA scores of the patients were, 
however, included in multifactorial linear regression models 
and they did not affect the results. Anxiety and depression are 
additional confounding factors (Vissers et al. 2012), the effects 
of which could not be taken into account retrospectively.
In conclusion, we found that previously diagnosed diabetes 
is a risk factor for persistent pain, and that severe obesity is 
a risk factor for a painful joint 1–2 years after primary hip 
or knee replacement. Patients and surgeons should know that 
these risk factors may reduce the benefits of joint replacement. 
Further research is needed to clarify the mechanisms underly-
ing the association between disorders of glucose metabolism 
and postoperative pain.
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